<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Endothelium-dependent vasodilation is impaired in clinical states of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> such as <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Individuals who have hyperinsulinemic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> have relatively elevated circulating levels of endothelin (ET)-1, suggesting that ET-1 may be important in the <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and alterations of vascular tone in these conditions </plain></SENT>
<SENT sid="2" pm="."><plain>In 8 lean subjects, 12 nondiabetic <z:mp ids='MP_0001261'>obese</z:mp> subjects, and 8 subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, we measured basal and <z:chebi fb="0" ids="6804">methacholine</z:chebi>-stimulated rates of leg blood flow (LBF) and total serum nitrates (NOx) before and after the intrafemoral arterial administration of BQ123, a specific blocker of ET(A) receptors </plain></SENT>
<SENT sid="3" pm="."><plain>BQ123 produced significant vasodilation in the <z:mp ids='MP_0001261'>obese</z:mp> and type 2 diabetic subjects (leg vascular resistance = mean arterial pressure/LBF fell by 34 and 36%; P &lt; 0.005) but not in the lean subjects (13%; P = NS, P = 0.018 comparing <z:hpo ids='HP_0000001'>all</z:hpo> groups) </plain></SENT>
<SENT sid="4" pm="."><plain>ET(A) blockade did not change basal NOx flux (NOx*LBF) </plain></SENT>
<SENT sid="5" pm="."><plain>This suggests increased basal ET-1 constrictor tone among <z:mp ids='MP_0001261'>obese</z:mp> and type 2 diabetic subjects </plain></SENT>
<SENT sid="6" pm="."><plain>BQ123 corrected the baseline defect in endothelium-dependent vasodilation seen in <z:mp ids='MP_0001261'>obese</z:mp> and type 2 diabetic subjects, suggesting an important contribution of ET-1 to <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> in these subjects </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast to basal conditions, stimulated NOx flux was augmented by BQ123 in <z:mp ids='MP_0001261'>obese</z:mp> and type 2 diabetic subjects but not in L subjects (P = 0.04), suggesting a combined effect of ET(A) blockade to reduce constrictor tone and augment dilator tone </plain></SENT>
<SENT sid="8" pm="."><plain>Endothelin seems to contribute to <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e> and the regulation of vascular tone in human <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>